Floatz logo

Ortho Tri Cyclen

Cardiovascular Diseases

Virginia Commonwealth UniversityPhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

60 Active assets in the Cardiovascular Diseases cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

Ortho Tri Cyclen is also rated in:

abdominal obesity-metabolic syndromeDormant
B
Indicative ·
62 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
52 / 100
View asset →
cystic fibrosisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →